All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
FDA lifts partial clinical hold on odronextamab trials in B-cell non-Hodgkin lymphomas
By Claire Baker
Bookmark this article
On December 14, 2020, it was reported that the U.S. Food and Drug Administration (FDA) placed a partial clinical hold on trials of odronextamab in B-cell non-Hodgkin lymphomas (B-NHL) following reports of Grade ≥3 cytokine release syndrome during step-up dosing.
On May 17, 2021, the FDA announced the lift of this partial hold, meaning that enrollment of patients with follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) to the affected trials, NCT02290951 (phase I) and NCT03888105 (phase II), will resume with immediate effect. The decision is based on the refined trial protocols that aim to further reduce the incidence of severe CRS.
- Regeneron Pharmaceuticals. Regeneron resumes enrollment of FL and DLBCL patients in odronextamab trials. https://investor.regeneron.com/static-files/f926fedf-8c6c-4f6f-a110-f295978c0c7f. Published May 17, 2021. Accessed May 19, 2021.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youNewsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox